# PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy

> **NCT07443696** · PHASE2 · RECRUITING · sponsor: **Sinotau Pharmaceutical Group** · enrollment: 40 (estimated)

## Conditions studied

- Ischemic Cardiomyopathy
- Heart Failure

## Interventions

- **DRUG:** Fasting XTR003/¹⁸F-FDG PET myocardial metabolic imaging
- **DRUG:** Glucose-loaded ¹⁸F-FDG PET Myocardial Metabolic Imaging

## Key facts

- **NCT ID:** NCT07443696
- **Lead sponsor:** Sinotau Pharmaceutical Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-18
- **Primary completion:** 2026-08
- **Final completion:** 2026-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07443696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07443696, "PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07443696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*